In8bio Company Insiders
INAB Stock | USD 0.31 0.01 3.33% |
In8bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding In8bio Inc suggests that all insiders are extremely bullish. In8bio employs about 39 people. The company is managed by 9 executives with a total tenure of roughly 91 years, averaging almost 10.0 years of service per executive, having 4.33 employees per reported executive.
In8bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-09-13 | Jeremy R Graff | Acquired 2500 @ 0.95 | View | ||
2023-08-25 | Patrick Mccall | Acquired 1000 @ 1.03 | View | ||
2023-08-24 | William Tai-Wei Ho | Acquired 23800 @ 1.05 | View | ||
2022-08-16 | William Tai-Wei Ho | Acquired 26315 @ 1.9 | View |
Monitoring In8bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
In8bio |
In8bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.7764) % which means that it has lost $0.7764 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8045) %, meaning that it created substantial loss on money invested by shareholders. In8bio's management efficiency ratios could be used to measure how well In8bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.93. In addition to that, Return On Capital Employed is expected to decline to -1.12. At present, In8bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 687.7 K, whereas Total Assets are forecasted to decline to about 25.1 M.As of November 27, 2024, Common Stock Shares Outstanding is expected to decline to about 21 M. In addition to that, Net Loss is expected to decline to about (13.8 M)
In8bio Workforce Comparison
In8bio Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,071. In8bio holds roughly 39.0 in number of employees claiming about 4% of equities under Health Care industry.
In8bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific In8bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on In8bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, In8bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brandt Peter C. over three weeks ago Acquisition by Brandt Peter C. of 253164 shares of In8bio at 0.395 subject to Rule 16b-3 | ||
William Ho over a month ago Disposition of 81967 shares by William Ho of In8bio at 1.25 subject to Rule 16b-3 | ||
Mccall Patrick over two months ago Acquisition by Mccall Patrick of 250000 shares of In8bio at 0.47 subject to Rule 16b-3 | ||
Roemer Alan S. over three months ago Acquisition by Roemer Alan S. of 33650 shares of In8bio at 1.47 subject to Rule 16b-3 | ||
Lawrence Lamb over three months ago Acquisition by Lawrence Lamb of 62826 shares of In8bio subject to Rule 16b-3 | ||
Kreis Leslie W. over six months ago Acquisition by Kreis Leslie W. of 574241 shares of In8bioInc at 1.0E-4 subject to Rule 16b-3 | ||
Epperly Corinne over six months ago Acquisition by Epperly Corinne of 54800 shares of In8bioInc at 1.04 subject to Rule 16b-3 | ||
Goswami Trishna over six months ago Acquisition by Goswami Trishna of 4098 shares of In8bioInc at 1.22 subject to Rule 16b-3 |
In8bio Notable Stakeholders
An In8bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as In8bio often face trade-offs trying to please all of them. In8bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting In8bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Patrick CPA | CFO Secretary | Profile | |
Pharm MPH | VP Communications | Profile | |
TaiWei Ho | President, CoFounder | Profile | |
William Ho | President, CoFounder | Profile | |
Trishna MD | Chief Officer | Profile | |
Kate Rochlin | Chief Officer | Profile | |
Lawrence Lamb | CoFounder VP | Profile | |
Kenneth LaMontagne | Sr Devel | Profile | |
Michael McNamara | Vice Accounting | Profile |
About In8bio Management Performance
The success or failure of an entity such as In8bio Inc often depends on how effective the management is. In8bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of In8bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the In8bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.89) | (0.93) | |
Return On Capital Employed | (1.07) | (1.12) | |
Return On Assets | (0.89) | (0.93) | |
Return On Equity | (1.20) | (1.14) |
Please note, the presentation of In8bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, In8bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of In8bio's management manipulating its earnings.
In8bio Workforce Analysis
Traditionally, organizations such as In8bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare In8bio within its industry.In8bio Manpower Efficiency
Return on In8bio Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 769.4K | |
Net Loss Per Executive | 3.3M | |
Working Capital Per Employee | 493.1K | |
Working Capital Per Executive | 2.1M |
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |